GLN-1062 是 galantamine 的前体药物，在阿尔兹海默症中有研究价值。

GLN-1062 is a pro-drug of galantamine and liberates galantamine on cleavage by a carboxyesterase in the brain.

GLN-1062 has more than 15-fold higher bioavailability in the brain than the same doses of galantamine. In animal models of drug-induced amnesia, GLN-1062 produced several fold larger cognitive improvement than the same doses of galantamine, without exhibiting any significant levels of gastrointestinal side effects that are typical for the unmodified drug and other inhibitors of cholinesterases, such as donepezil and rivastigmin. In the ferret, dramatically reduced emetic and behavioral responses were observed when GLN-1062 was administered instead of galantamine[1].

224169-27-1

C24H25NO4

391.46

GLN-1062

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years